Investors-Gan & Lee

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Investors

Investors Financial Reports IR Appointment

FY2024 semi-annual Financial Performance Overview

Operating Income (CNY)

1.315Billion
Increase by 6.9% YOY
Net Profit Attributable Parent (CNY)

299 Million
Increase by 122.8% YOY
Sales Income in China (CNY)

1.188Billion
Increase by10.7% YOY
International Sales Income (CNY)

125Million
Increase by 15.9% YOY
R&D Input Ratio (R&D Input/Operating Income)

21.1%
R&D Investment 277 Million CNY
Equity Incentive in 2024 (87 Employees Granted)

7.04 Million
Shares of Restricted Stock Total Shares before the Grant of the Company 1.1849%

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Operating Income (CNY)

Net Profit Attributable Parent (CNY)

Sales Income in China (CNY)

International Sales Income (CNY)

R&D Input Ratio (R&D Input/Operating Income)

Equity Incentive in 2024 (87 Employees Granted)

Subscribe